摘要
目的 探讨14-3-3 ε蛋白在膀胱尿路上皮癌（Buc）中的表达及其临床病理意义.方法 采用免疫组织化学EnVision法检测14-3-3 ε蛋白在10例癌旁组织、25例低度恶性Buc[包括5例乳头状瘤、10例具有低度恶性潜能的尿路上皮癌（PUNLMP）、10例低级别尿路上皮癌]、21例高度恶性Buc（包括11例高级别尿路上皮癌、10例浸润性癌）中的定位及表达,并分析其与各临床指标的关系.结果 14-3-3 ε蛋白阳性着色部位为细胞质,癌旁组织阳性表达率为90.0％（9/10）,低度恶性Buc为72.0％（18/25）,高度恶性Buc为14.3％（3/21）,其表达量随病理分级增高而降低,而与其他临床病理参数无相关性.高度恶性Buc与低度恶性Buc间、高度恶性Buc与癌旁组织间阳性表达率差异均有统计学意义（均P＜0.05）.结论 14-3-3 ε蛋白的表达在膀胱癌的发生、发展中发挥着重要的作用,14-3-3 ε有可能是Buc早期诊断及“两类癌”分类的一个生物学标志物,具有潜在的临床应用价值.
Objective To investigate the expression of 14-3-3ε protein in the bladder urothelial carcinoma （BUC） and to explore its association with the clinicopathologic features.Methods The bladder urothelial carcinoma samples were divided into three groups：normal control group of 10 cases,low-grade malignant BUC group of 25cases （includes 5 cases of papilloma,10 cases of PUNLMP and 10 cases of low grade non-invasive papillary urothelial carcinoma）,high-grade malignant BUC group of 21 cases （includes 11 cases of high-grade non invasive papillary urothelial carcinoma and 10cases of infiltrating carcinoma）.The expression and location of 14-3-3ε in three groups were detected by immunohistochemical EnVision and the relationship with clinicopathologic parameters was analyzed.Results 14-3-3ε expression was observed in the cytoplasm of the cell.The expression of 14-3-3ε in normal control group was 90 % （9/10）,low-grade malignant BUC group was 72.0 % （18/25）,high grade malignant BUC group was 14.3 % （3/21）.It correlated with histological grading but had not showed correlation with other clinicopathologic parameters.There was significant difference in 14-3-3ε expression between the high grade malignant BUC group and the low-grade malignant BUC group,the high grade malignant BUC group and norml control group （all P 〈 0.05）.Conclusions 14-3-3ε plays an important role in carcinogenesis of BUC.It may be a biomarker for early diagnosis and classification of BUC and shows promise for clinic application.
出处
《肿瘤研究与临床》
CAS
2014年第10期670-672,676,共4页
Cancer Research and Clinic
